Skip to main content
Midas Edge

BIOADAPTIVES, INC.

For the period ended Dec 31, 2025. Filed Apr 14, 2026.

View on SEC.gov

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2025 · Filed Apr 14, 2026

BDPTStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Consolidated Statements of Stockholders’ Deficit

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

Additional
Series A Preferred stock · Series B Preferred stock · Series C Preferred stock · Series D Preferred stock · Common stock · paid-in · Subscription · Accumulated
Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · Shares · Amount · capital · receivable · Deficit · Total
Balance, December 31, 20239,500$17,500$1-$--$-5,971,728$597$6,616,915$-$(8,264,145)$(1,646,631)
Series A preferred stock issued for license fee1,667---------1,500--1,500
Series B preferred stock issued for license fee--1,667-------3,000--3,000
Series B preferred stock issued for settlement of debt - related party--500-------1,500--1,500
Series C preferred stock issued for purchase of inventory----1,000,000100----59,900--60,000
Series D preferred stock issued for cash------50,0005--299,995(5,885)-294,115
Series D preferred stock issued for compensation------22,6872--208,869--208,871
Common stock issued for conversion of debt--------2,239,794224202,419-202,643
Reverse split adjustment--------3,904-----
Debt forgiveness----------310,245--310,245
Net loss for the period------------(899,161)(899,161)
Balance, December 31, 202411,167$19,667$11,000,000$10072,687$78,215,426$821$7,704,343$(5,885)$(9,163,306)$(1,463,918)
Common stock issued for conversion of Series D preferred stock------(8,333)(1)833,30083(82)---
Series D preferred stock issued for compensation------94,11310--414,990--415,000
Series D preferred stock issued for cash------39,8684--299,996--300,000
Common stock issued for conversion of debt--------2,960,000296147,794148,090
Stock option compensation----------28,670--28,670
Reverse split adjustment--------(1)-----
Net loss for the period------------(1,557,898)(1,557,898)
Balance, December 31, 202511,167$19,667$11,000,000$100198,335$2012,008,725$1,200$8,595,711$(5,885)$(10,721,204)$(2,130,056)

F- 5

Table of Contents

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.